Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-αv integrin monoclonal antibody, despite widespread tissue binding

Clinical Cancer Research

Volumn 11, Issue 19 I, 2005, Pages 6959-6965

  Martin, Pauline L ^a   Jiao, Qun ^a   Cornacoff, Joel ^a   Hall, William ^b   Saville, Bradley ^b   Nemeth, Jeffrey A ^a   Schantz, Allen ^a   Mata, Marielena ^a   Jang, Haishan ^a   Fasanmade, Adedigbo A ^a   Anderson, Lisa ^b   Graham, Martin A ^a   Davis, Hugh M ^a   Treacy, George ^a  

^a CENTOCOR INC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAV INTEGRIN ANTIBODY; KETOROLAC; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CNTO 95; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAM; ENDOTHELIUM CELL; EPITHELIUM CELL; FEMALE; GROWTH PLATE; HEART RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACACA; MALE; NONHUMAN; PLACENTA; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; AORTA; AREA UNDER CURVE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAV; MACACA FASCICULARIS; MALE; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PATHOLOGIC; PLACENTA; PROTEIN BINDING; TIME FACTORS; WOUND HEALING;

EID: 26444548107     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2623     Document Type: Article

References (22)

1. Eliceiri BP, Cheresh DA. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103:1227-30.
2. Wayner EA, Orlando RA, Cheresh DA. Integrins αvβ3 and αvβ5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol 1991;113:919-29.
3. Friedlander M, Brooks PC, Shaffer RW. Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv integrins. Science 1995;270: 1500-2.
4. Trikha M, Zhou Z, Nemeth JA, et al. CNTO 95, a fully human monoclonal antibody that inhibits α-v integrins, has anti-tumor and anti-angiogenic activity in vivo. Int J Cancer 2004;110:326-35.
5. Davis HM, Prabhakar U, Jang H, et al. A rational approach for a phase I clinical study design to evaluate CNTO 95, a novel, fully human anti-αv monoclonal antibody (mAb), in patients with solid tumors. Proc Am Soc Clin Oncol 2004;22: A2609.
6. Jayson GC, Mullamitha S, Ton C, et al. Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors. Proc Am Soc Clin Oncol 2004;22: A3119.
7. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin α(v)β3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998;4:2625-34.
8. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25: 581-611.
9. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin αvβ3. Clin Cancer Res 2000;6:3056-61.
10. Ryan AM, Eppler DB, Hagler KE, et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999; 27:78-86.
11. Fraser HM, Wilson H, Rudge JS, Weigand SJ. Single injections of vascular endothelial growth factor Trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function. J Clin Endocrinol Metab 2005; 90:1114-22.
12. Fraser HM, Wulff C. Angiogenesis in the primate ovary. Reprod Fertil Dev 2001;13:557-66.
13. A40. J Clin Endocrinol Metab 2001;86: 3377-86.
14. Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser MH. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor trap R1R2. Endocrinology 2002;143:2797-807.
15. Zimmermann RC, Xiao E, Bohlen P, Ferin M. Administration of antivascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in the rhesus macaque. Endocrinology 2002;143:2496-502.
16. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-4.
17. Bugelski PJ, Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther 2004;6:10-6.
18. Stephens S, Emtage O, Vetterlein LC, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995;85:668-74.
19. Eskens FALM, Dumez H, Hoekstra R, et al. Phase I and pharmacokinetic study of continuous twice weekly i.v. administration of cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumors. Eur J Cancer 2003;39:917-26.
20. Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumastatin, a fragment of collagen IV α3 chain, are generated by MMP-3 proteolysis and suppress angiogenesis via αvβ3 integrin. Cancer Cell 2003;3:589-601.
21. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins. Cell 1998;95:507-19.
22. Yang JT, Rayburn H, Hynes RO. Embryonic mesodermal defects in α5 integrin-deficient mice. Development 1993;119:1093-105.